# Pharmacokinetics & Metabolism
### The Bioavailability Problem — and What Changed in 2025
Shikonin is highly lipophilic and poorly water soluble. In biological fluids it does not dissolve readily, which limits how much reaches the bloodstream following oral administration and how much ultimately arrives at tumour tissue.
For decades this was not a visible problem in the research literature — because the research did not need to solve it. Laboratory studies use cell culture media and injectable preparations where solubility can be managed directly. Researchers compensated by dissolving shikonin in DMSO or ethanol carriers, or by delivering it via intraperitoneal injection in animal models. The compound reached cells reliably in those systems. The oncology findings accumulated. The bioavailability gap was real but sitting quietly in the background of every study.
The practical consequence was significant: all of that mechanistically coherent, well-replicated laboratory work existed in a system that bypassed the very problem any person trying to use shikonin orally would face. The concentrations achieved in cell-line studies — often 2–10 μM — had no reliable oral pathway to match them.
That gap began to close in a meaningful way when a consumer-grade **liposomal shikonin formulation** became commercially available. Liposomal encapsulation wraps the lipophilic shikonin molecule in a phospholipid shell — the same basic structure as cell membranes — which dramatically improves dispersibility in water-based biological fluids and protects the compound from degradation before absorption. One formulation (LongLifeLipoTech™) uses phospholipids from organic sunflower lecithin combined with chitosan to form neutrally charged liposomes, delivering 30 mg of shikonin per capsule.
Liposomal delivery technology has been validated for shikonin in preclinical settings since at least 2016, with animal models showing substantially improved bioavailability compared to free shikonin. The 2025 availability of a consumer-grade liposomal capsule is the first time that formulation advantage has been accessible outside a research laboratory.
This is a meaningful development. It does not close the clinical evidence gap — no human pharmacokinetic data yet confirms what plasma or tissue concentrations a liposomal oral dose actually achieves in people. But it does mean that for the first time, the delivery mechanism exists for oral dosing to at least approach the territory the oncology research has been mapping. Whether it reaches the concentrations the most important studies used remains an open question — and an important one to watch as data emerges.\
\
Get more details on the MCS Formulas LongLifeLipoTech™) that uses phospholipids from organic sunflower lecithin combined with chitosan to form neutrally charged liposomes, delivering 30 mg of shikonin per capsule [here ](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sourcing-quality-shikonin.md)
***
### Why the concentration problem matters
Many mechanistic papers use concentrations in the low micromolar range.
Those levels are useful for understanding biology.
They may or may not be achievable with raw or liposomal oral shikonin products in humans.
Dose translation from mouse to human is one of the biggest weak points in todays Shikonin evidence base.
### Metabolism
Shikonin appears to undergo hepatic metabolism, including oxidative processing and conjugation.
The oncology relevance of its metabolites remains poorly characterised.
That is a major contrast with compounds where active metabolites are already well mapped.
### Tissue distribution
Preclinical work suggests tumour exposure can occur in xenograft models.
What remains unknown is whether human tumour tissue can reach concentrations needed for PKM2 inhibition, ER disruption, or necroptosis induction with available formulations.
### Formulation approaches
Most translational work focuses on delivery improvement.
The main strategies include:
* liposomal shikonin as in the
* nanoparticle encapsulation (research only)
These approaches improve dispersibility and may improve tumour delivery in preclinical settings.
They are still not the same as established clinical formulations.
### What has changed recently
There is now a purpose-built liposomal shikonin formula on the market.
At present, it appears to be the only liposomal shikonin product currently available commercially.
That matters because it directly addresses the compound's main delivery weakness.
We still do not have human oncology pharmacokinetic data showing what plasma or tumour levels liposomal shikonin achieves.
For product-quality context, see [Sourcing Quality Shikonin](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sourcing-quality-shikonin.md).
### How to think about liposomal shikonin now
Delivery is starting to catch up with the biology.
That is real progress.
A liposomal system will no doubt improve dispersion, absorption, and tissue exposure.
It also does not remove the need for caution around interactions, and dose interpretation.
### Bottom line
The mechanism case is strong,
and the formulation story is improving
and the human pharmacokinetic proof is still missing.
### Key references
Shikonin as a dietary phytochemical with multi-target anticancer activity — formulation advances including nanoparticles and liposomes. *Nutrients* (2025).\
Shikonin Pro Liposomal — LongLifeLipoTech™ consumer formulation, 30 mg per capsule. *MCS Formulas* (2025).\
Promising nanomedicines of shikonin for cancer therapy — liposomal and nanoparticle delivery systems review. *PMC* (2023).\
RGD-modified liposomes encapsulated with shikonin for targeted melanoma treatment — liposomal bioavailability and tumour retention data. *Frontiers in Oncology* (2025).\
Pharmacological properties of shikonin — bioavailability and lipophilicity background. *Deutsche Nationalbibliothek review* (2013).\
\
\
Ahmad F et al. (2024). Shikonin in breast cancer treatment — bioavailability and formulation discussion. *Journal of Pharmacy and Pharmacology.*\
A shikonin derivative induces excessive autophagy in pancreatic cancer — derivative potency and formulation. *Chemistry & Biodiversity* (2025).\
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pharmacokinetics-and-metabolism.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.